Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
Information source: Washington University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Resistant Solid Malignancies
Intervention: Temsirolimus (Drug); Docetaxel (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Washington University School of Medicine Official(s) and/or principal investigator(s): Joel Picus, M.D., Principal Investigator, Affiliation: Washington University School of Medicine
Summary
Rationale:
The Mammalian Target of Rapamycin (mTOR) is a large polypeptide serine/threonine kinase of
289 kDa; kinases have been shown to be important regulators of cancer cell cycle,
proliferation, invasion, and angiogenesis, and mTOR has been shown to have a key role in the
signaling of malignant cell growth, proliferation, differentiation, migration, and survival.
Inhibition of mTOR would result in arrest of cell growth in the G1 phase of the cell cycle.
Temsirolimus (CCI-779) is a soluble ester analogue of rapamycin (sirolimus) which has shown
impressive in vitro and in vivo cytostatic activity in selectively inhibiting mTOR. In
animal models, temsirolimus has demonstrated an impressive cytostatic effect on a wide
variety of cancer cells. In vitro, it inhibited the growth of human T-cell leukemia,
glioblastoma, melanoma, prostate, breast, renal cell, and pancreatic cells, all of which
showed particular sensitivity to temsirolimus, with significant growth inhibition at
concentrations of less that 0. 01micrometers. In Phase I trials, temsirolimus has been
investigated as a single agent on a weekly schedule as well as daily for 5 days every other
week, and evidence of activity was observed over the entire dose range (15 - 220 mg/m2) in
patients with both breast and renal cancer. There was no apparent relationship between
exposure and clinical benefit, suggesting that the inhibition of mTOR may be achieved at
doses well below dose levels that result in dose limiting toxicities. Major tumor responses
were noted in Phase I trials in patients previously treated with lung, breast, renal as well
as neuroendocrine tumors. Minor responses were noted in soft tissue sarcoma, endometrial,
and cervical carcinoma.
Docetaxel is a taxane analog which is active against many solid tumors including breast,
non-small cell lung, prostate, gastric, ovarian, head and neck, and pancreatic cancers, soft
tissue sarcoma, and melanoma. It has been shown in several Phase III studies to have
clinically significant activity in several solid tumors.
We propose treating patients with resistant solid malignancies with docetaxel and
temsirolimus. In a study using human breast cancer cell lines, mTOR inhibition with
rapamycin had a synergistic cytotoxic effect with paclitaxel. Given the novel mechanism of
action of mTOR inhibitors and known synergistic activity of an mTOR inhibitor, rapamycin,
with a taxane, paclitaxel, in vitro, we envision that this regimen would be highly active in
patients with solid tumor malignancies.
Objectives:
Primary
- To define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of
temsirolimus in combination with pegylated liposomal doxorubicin in patients with
resistant solid malignancies.
- To determine the incidence and severity of other toxicities of temsirolimus in
combination with pegylated liposomal doxorubicin in patients with resistant solid
malignancies.
Secondary
- To assess the pharmacokinetic profile of temsirolimus in combination with pegylated
liposomal doxorubicin.
- To determine any anti-tumor activity and response to the combination of temsirolimus
and pegylated liposomal doxorubicin in treatment of patients with resistant solid
malignancies.
Clinical Details
Official title: Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To define the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.To determine the incidence and severity of other toxicities of temsirolimus in combination with pegylated liposomal doxorubicin in patients with resistant solid malignancies.
Secondary outcome: To assess the pharmacokinetic profile of temsirolimus in combination with pegylated liposomal doxorubicin.To determine any anti-tumor activity and response to the combination of temsirolimus and pegylated liposomal doxorubicin in treatment of patients with resistant solid malignancies.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion and Exclusion Criteria:
- Patients must have a histologically or cytologically proven solid malignancy which is
resistant to conventional therapy or for which no effective therapy is known.
- Patients with measurable or non-measurable disease are eligible for entry to this
study. In addition, patients without measurable or non-measurable disease are also
eligible.
- Patients must have recovered from the acute toxic effects of all prior chemotherapy,
immunotherapy, or radiotherapy prior to entering this study. Neuropathy must have
recovered to grade 1. No chemotherapy or radiotherapy may be given within 4 weeks
prior to the start of protocol treatment.
- Patients must be ≥18 years old.
- ECOG 0-2 at study entry.
- Patients must have a life expectancy of greater than 8 weeks.
- Required Laboratory Values:
- absolute neutrophil count ≥1,500/mm3
- platelets ≥100,000/mm3
- hemoglobin ≥9. 0 g/dL
- total bilirubin ≤1. 5 x ULN
- AST(SGOT)/ALT(SGPT) ≤1. 5 x ULN (≤2. 5 x ULN for patients with liver metastases
- alkaline phosphatase ≤2. 5 x ULN
- creatinine ≤1. 5 x ULN OR
- creatinine clearance ≥60 mL/min/1. 732 for patients with creatinine levels
above 2. 0 mg/dl
- serum cholesterol ≤350 mg/dL /9. 0 mmol/L (fasting)
- triglycerides ≤400 mg/dL (fasting)*
- albumin ≥3. 0 mg/dL
- PT/INR ≤1. 5, unless the patient is on full dose warfarin or stable
dose of LMW heparin with a therapeutic INR of >1. 5 - ≤3
- Patients cannot be receiving enzyme-inducing antiepileptic drugs (EIAEDs; e. g.,
phenytoin, carbamazepine, phenobarbital) nor any other CYP3A4 inducer such as
rifampin or St. John's wort, as these may decrease temsirolimus levels.
- Patients with known hypersensitivity reactions to macrolide antibiotics (such as
erythromycin, clarithromycin, and azithromycin) are not eligible for this trial.
- For all sexually active patients, the use of adequate contraception (hormonal or
barrier method of birth control) will be required prior to study entry and for the
duration of study participation. Non-pregnant status will be determined in all women
of childbearing potential. Pregnant and nursing women are not eligible.
- Patients must not have active CNS disease.
- Patients must have recovered from uncontrolled intercurrent illness including, but
not limited to, ongoing or active infection, symptomatic congestive heart failure,
unstable angina pectoris or cardiac arrhythmia.
- Patients must have signed a Washington University, Human Research Protection Office
(HRPO) approved informed consent. The patient should not have any serious medical or
psychiatric illness that would prevent either the giving of informed consent or the
receipt of treatment.
Locations and Contacts
Washington University School of Medicine, St. Louis, Missouri 63110, United States
Additional Information
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Related publications: Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006 Feb 10;124(3):471-84. Review. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005 Aug 10;23(23):5386-403. Epub 2005 Jun 27. Review. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs. 2006 Jun;17(5):487-94. Review. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev. 2006 Feb;16(1):78-84. Epub 2005 Dec 15. Review. Elit L. CCI-779 Wyeth. Curr Opin Investig Drugs. 2002 Aug;3(8):1249-53. Review. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003 Aug;3(4):371-7. Review. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 2003 Nov;4(5):343-8. Review. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006 Jun 1;66(11):5549-54. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004 Oct 18;91(8):1420-4. Review. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006 Feb 1;107(3):1149-55. Epub 2005 Sep 29. Hidalgo M, Rowinsky E, Erlichmann C, et al. A Phase I and Pharmacological Study of CCI-779, a Rapamycin Ester Cell Cycle Inhibitor. Annals of Oncology 11(Suppl4): 133, 2000. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004 Jun 15;22(12):2336-47. Epub 2004 May 10. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol. 2003 Jun;14(6):931-7. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005 Aug 10;23(23):5347-56. Epub 2005 Jun 27. Oza A, Elit L, Biagi J, Gotlieb W, Tonkin K, Tsao MN, et al. A Phase II Study of Temsirolimus (CCI-779) in Patients with Metastatic and/or Recurrent Endometrial Cancer. Clinical Cancer Research 11: 9099s, 2005 Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005 Aug 10;23(23):5314-22. Epub 2005 Jun 13. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 1;22(5):909-18. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group (E1500). A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol. 2007 Nov;2(11):1036-41. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 1;104(5):1045-8. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD; North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug;23(4):357-61. Hudes G, Carducci M, Tomczak P, et al. A Phase 3, Randomized, 3-arm Study of Temsirolimus (TEMSR) or Interferon-alpha (IFN) or the Combination of TEMSR + IFN in the Treatment of First-Line, Poor-Risk Patients with Advanced Renal Cell Carcinoma (adv RCC). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings; 24: LBA4, 2006. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12. Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc). 2006 Apr;42(4):265-79. Review. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun;18(12):2354-62. Erratum in: J Clin Oncol. 2004 Jan 1;22(1):209. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005 Aug 20;23(24):5542-51. Charles KA, Rivory LP, Stockler MR, Beale P, Beith J, Boyer M, Clarke SJ. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet. 2006;45(6):611-22. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006 Apr;129(4):1031-8. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005 Nov 20;23(33):8389-95. Ford HE, Yap YS, Miles DW, Makris A, Hall M, Miller L, Harries M, Smith IE, Johnston SR. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006 Dec;58(6):809-15. Epub 2006 Mar 10. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004 Oct 15;10(20):7031-42. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. Yazbeck VY, Georgakis GV, Li Y, and Younes A. The mTOR Inhibitor CCI-779 (Temsirolimus) Downregulates p21 and Induces Cell Cycle Arrest and Autophagy in Mantle Cell Lymphoma (MCL). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings; 24:7573, 2006. Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006 Aug;42(12):1875-80. Epub 2006 Jun 27.
Starting date: March 2008
Last updated: May 22, 2013
|